Phio Pharmaceuticals Corp. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
CEO Robert J. Bitterman and CFO Lisa C. Carson certified the June 30, 2026 10-Q filing on August 6, 2026, affirming no material misstatements, fair presentation of financials, and adequate disclosure controls and internal reporting procedures. No substantive operational, financial, or transactional changes are disclosed in these boilerplate Exhibits 31.1, 31.2, and 32.1.
Why this rating
These are mandatory, standardized SOX officer certifications with no operational or financial substance disclosed. Purely administrative.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.